Malta officially legalised medicinal cannabis in April 2018, with the adoption of the Production of Cannabis for Medicinal and Research Purposes Act.
Keen to be a central enabler of Europe’s medical cannabis sector, Malta is leveraging its renowned pharmaceutical regulatory framework to position itself as a strategic hub for the global cannabis market.
A handful of leading cannabis companies have chosen to set up facilities in Malta, taking advantage of the country’s expertise in pharmaceutical manufacturing and business-friendly operating environment.
Materia is in the process of retrofitting an existing 34,000 sq. ft. facility in the Ħal Far industrial estate, which will ultimately be a state-of-the-art production hub used to process and formulate cannabis products.
Materia’s Malta facility will convert cannabis biomass into EU-GMP certified flower or oils to be distributed throughout Europe and the world.
Our expert Malta team brings together strong business acumen with decades of collective pharmaceutical experience across the key departments of production, quality control, quality assurance, pharmacovigilance and security.